Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
A Prospective Observational Study to Develop and Validate a Multimodal Deep Learning Model Integrating Peripheral Oxygen Saturation and Ballistocardiography Signals for the Prediction of Apnea-Hypopnea Index in Patients With Suspected Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a common sleep disorder associated with cardiovascular, metabolic, and neurocognitive complications. The standard diagnostic test for OSA is in-laboratory polysomnography (PSG), which can be costly, labor-intensive, and inconvenient for repeated or large-scale screening. Therefore, there is a need for a convenient and non-invasive method to help identify individuals who may be at risk for OSA.
This prospective observational study aims to develop and clinically validate a multimodal deep learning model that integrates peripheral oxygen saturation (SpO₂) signals and ballistocardiography (BCG) data collected using a smart mattress system to estimate the apnea-hypopnea index (AHI). Adult participants undergoing routine overnight PSG for suspected OSA will be enrolled. During sleep, synchronized SpO₂ and BCG signals will be recorded non-invasively.
The performance of the deep learning model will be evaluated by comparing the predicted AHI values with AHI values derived from PSG. This study seeks to evaluate whether this practical, non-invasive, and scalable approach may support early identification of OSA risk and improve access to sleep disorder assessment in both clinical and home-based settings.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
This is a prospective observational cohort study designed to develop and validate a multimodal deep learning-based model for estimating obstructive sleep apnea (OSA) severity. Adult participants with suspected OSA who are scheduled to undergo overnight in-laboratory polysomnography (PSG) will be recruited at Fu Jen Catholic University Hospital.
During the PSG examination, participants will simultaneously undergo non-invasive physiological signal acquisition using a smart mattress system equipped with ballistocardiography (BCG) sensors, along with continuous peripheral oxygen saturation (SpO₂) monitoring. These signals will be time-synchronized with PSG recordings. No experimental intervention or alteration to standard clinical care will be performed.
Multimodal deep learning algorithms incorporating convolutional neural networks and sequence-based architectures will be developed to analyze SpO₂ and BCG signals and to estimate the apnea-hypopnea index (AHI). Model performance will be assessed by comparing predicted AHI values with PSG-derived AHI using predefined statistical metrics.
The primary objective is to evaluate the accuracy of AHI prediction using the proposed multimodal model. Secondary objectives include assessment of model discrimination for OSA severity classification and exploratory analyses of physiological signal features associated with sleep-disordered breathing. All analyses will be conducted using de-identified data. This study does not involve U.S. FDA-regulated drugs or devices and is not conducted under an investigational new drug application or investigational device exemption.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ke-Yun Chao Principal Investigator
- Telefonnummer: +886-905-301-879
- E-Mail: C00152@mail.fjuh.fju.edu.tw
Studienorte
-
-
New Taipei City
-
New Taipei City, New Taipei City, Taiwan, 24352
- Rekrutierung
- Fu Jen Catholic University Hospital
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: +886-2-2905-2000
- E-Mail: Ck_qq@hotmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult individuals aged 20 years or older who are referred to Fu Jen Catholic University Hospital for in-laboratory polysomnography due to suspected obstructive sleep apnea will be invited to participate. The study population includes participants with a wide range of apnea-hypopnea index values, including individuals without obstructive sleep apnea based on polysomnography results.
Beschreibung
Inclusion Criteria:
- Adults aged 20 years or older.
- Individuals referred for in-laboratory polysomnography due to suspected obstructive sleep apnea.
- Able and willing to provide informed consent.
Exclusion Criteria:
- Inability to provide informed consent.
- Presence of conditions that may interfere with sleep signal acquisition, as determined by the investigator.
- Prior diagnosis of sleep disorders other than obstructive sleep apnea that could confound study results.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Adults With Suspected Obstructive Sleep Apnea
This cohort includes adult participants with suspected obstructive sleep apnea who are scheduled to undergo overnight in-laboratory polysomnography. All participants will receive standard clinical polysomnography while simultaneously undergoing non-invasive physiological signal acquisition using a smart mattress system and peripheral oxygen saturation monitoring. No experimental intervention or treatment assignment is performed. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean absolute error of apnea-hypopnea index estimation
Zeitfenster: Two overnight assessments per participant: one in-laboratory polysomnography night and one subsequent home sleep monitoring night.
|
Mean absolute error (MAE) will be calculated as the average absolute difference between the apnea-hypopnea index (AHI) predicted by the multimodal deep learning model using peripheral oxygen saturation (SpO2) and ballistocardiography (BCG) signals collected during home sleep monitoring and the AHI measured by in-laboratory polysomnography (PSG). The analysis will include participants with evaluable paired PSG and home monitoring data. MAE will be reported in events per hour, with lower values indicating better predictive performance. |
Two overnight assessments per participant: one in-laboratory polysomnography night and one subsequent home sleep monitoring night.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- FJUH115580
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant data will not be shared publicly.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .